OREX showing some life, any chance to close the gap above? Vivus Inc. (VVUS) said a two-year study found its weight-loss drug Qnexa also reduces blood pressure and the required use of antihypertension medications, while rival Orexigen Therapeutics Inc. (OREX) said a separate one-year study showed patients using its obesity drug Contrave maintained normal blood pressure levels for a 24-hour period.
Vivus shares surged 10% at $6.95 premarket. As of Friday's $6.31 close, the stock had fallen 33% so far this year. Orexigen shares got a 7.6% bump to $3.10. As of Friday's $2.88 close, the stock had fallen 64% so far this year.
Long-term data from Vivus's Sequel study showed that patients who received the top dose had sustained weight loss greater than 10% over two years. This weight loss led to reductions in blood pressure and triglyceride while improving lipid levels.
Market Data 
Markets 
AI
